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Abstract
Using circulating inflammatory markers and magnetic resonance imaging (MRI), recent
studies have associated inflammation with brain volumetric measures. Macrophage Inhibi-
tory Cytokine–1 (MIC-1/GDF15) is a divergent transforming growth factor – beta (TGF-β)
superfamily cytokine. To uncover the underlying mechanisms of the previous finding of a
negative association between MIC-1/GDF15 serum levels and cognition, the present study
aimed to examine the relationship of circulating MIC-1/GDF15 levels with human brain gray
matter (GM) volumes, in a community-dwelling sample aged 70–90 years over two years
(Wave 1: n = 506, Wave 2: n = 327), of which the age-related brain atrophy had been previ-
ously well defined. T1-weighted MRI scans were obtained at both waves and analyzed
using the FMRIB Software Library and FreeSurfer. The results showed significantly nega-
tive associations between MIC-1/GDF15 serum levels and both subcortical and cortical GM
volumes. GM volumes of the whole brain, cortex, temporal lobe, thalamus and accumbens
showed significant mediating effects on the associations between MIC-1/GDF15 serum lev-
els and global cognition scores. Increases in MIC-1/GDF15 serum levels were associated
with decreases in cortical and subcortical GM volume over two years. In conclusion, MIC-1/
GDF15 serum levels were inversely associated with GM volumes both cross-sectionally
and longitudinally.
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Introduction
Inflammation is associated with neuropsychiatric disorders, such as Alzheimer’s disease [1],
schizophrenia [2], bipolar disorder [3], and major depressive disorder [4]. It is also a feature
of atherosclerosis [5] and stroke [6, 7]. Some recent studies have attempted to better under-
stand the pathogenic mechanisms underlying these associations by examining the relation-
ship between magnetic resonance imaging (MRI) of brain structures and markers of
inflammation, such as interleukins (ILs) [8–11]. In addition, there are defined relationships of
serum levels of tumor necrosis factor—alpha (TNF-α) with total brain volume [12] and hip-
pocampal volume [13], as well as C-reactive protein (CRP) serum levels with temporal gray
matter volume [14] and global and regional white matter integrity measured by fractional an-
isotropy [15].
A recent study from our group revealed that serumMacrophage Inhibitory Cytokine—1
(MIC-1/GDF15) levels were associated with cognitive decline [16]. The current study, there-
fore, aimed to determine if this relationship extended to changes in gray matter volume. MIC-
1/GDF15 is a divergent member of the transforming growth factor-β (TGF-β) superfamily
[17–20]. Its expression is elevated in disease status such as injury [21], malignancy [22–24] and
inflammation [19, 25]. Unlike most other inflammatory pathway cytokines regulated by the
transcription factor Nuclear Factor-kappa B (NFkB) [26, 27], MIC-1/GDF15 is induced by al-
ternate transcription factors including p53 [28, 29] and Egr-1 [30]. Further, MIC-1/GDF15 is
not an acute phase reactant as its serum level is not altered by administration of high doses of
corticosteroids [25]. Therefore, it is likely that MIC-1/GDF15 serum levels reflect the activity
of cellular processes not sampled by the more commonly studied inflammation associated
cytokines.
Whilst MIC-1/GDF15 serum levels are elevated in inflammatory conditions like atheroscle-
rosis [31] and rheumatoid arthritis [25], current evidences from animal models suggest that it
may be anti-inflammatory [18, 21, 32], neurotrophic and neuroprotective [20]. Like many
other neurotrophic cytokines, MIC-1/GDF-15 mRNA and protein are expressed in the central
and peripheral nervous systems throughout fetal development and into adulthood [20, 21]. In
adulthood, MIC-1/GDF15 is mainly expressed in the choroid plexus and secreted into cerebro-
spinal fluid (CSF). Its expression is up-regulated in central nervous system (CNS) injury [21]
and intracranial tumors [33], and is elevated in the CSF of patients with CNS tumors and HIV
associated neurological disease [18]. MIC-1/GDF15 serum levels have also been related to cog-
nitive decline in the elderly; a recent study from our group identified a strong cross-sectional
and prospective negative association between MIC-1/GDF15 serum levels and cognitive func-
tion [16]. A MIC-1/GDF15 serum level exceeding 2764 pg/ml was associated with a 20%
chance of decline from normal to MCI or dementia.
In our previous study [34], we reported that the age-related brain atrophy over two years,
and gender and education impacts on the brain decline in the same sample as the current
study. Our findings were similar to those from some benchmark longitudinal studies [35–38].
In this well-defined sample, our current study aimed at investigating the associations between
MIC-1/GDF15 serum levels and brain gray matter (GM) volumes, in order to 1) examine the
contribution of peripheral inflammation and/or MIC-1/GDF15 itself to the age-related brain
decline, and 2) elucidate the mechanisms that may underlie the relationship between MIC-1/
GDF15 and cognitive decline. Based on the findings from previous studies, we hypothesize that
an elevated level of systemic MIC-1/GDF15 serum levels would correlate with GM atrophy in
cortical and subcortical regions, and that the GM volume is a mediator of the previously ob-
served relationships between MIC-1/GDF15 serum levels and cognition.
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Participants were from the Sydney Memory and Ageing Study (MAS), a community-based lon-
gitudinal study recruiting randomly through the electoral roll from two federal government
areas in Sydney, New South Wales, Australia. The study background, methods and sample
characteristics were reported in details elsewhere [39]. Briefly, 1037 community-dwelling non-
demented older individuals aged 70–90 years received neuropsychological tests, medical assess-
ments, and a telephone interview of an informant. The exclusion criteria included dementia,
mental retardation, psychotic disorder including schizophrenia or bipolar disorder, multiple
sclerosis, motor neuron disease, developmental disability, or progressive malignancy. Individu-
als with a non-English speaking background to ensure the validity of completing assessments
are also disqualified.
The current report involved participants fromWave 1 andWave 2 of the MAS (two years
apart; Table 1). At Wave 1, 506 individuals received both MRI scans and blood tests, and were
included in Wave 1 cross-sectional analyses. The number of participants decreased to 327 for
Wave 2 due to death or participant drop out. Of the 327 participants, 247 received both MRI
scans and blood tests at both waves, and were therefore included in longitudinal analyses.
Table 1. Sample characteristics.
Wave 1 Wave 2
N (MIC-1/GDF15) 888 585
N (MRI) 551 420
N (have both MRI and MIC-1) a 506 327
Age (years) (Mean ± SD) 78.28 ± 4.59 79.68 ± 4.58
% Female 53.6% 51.8%
Education (years) 11.80 ± 3.61 11.93 ± 3.71
Levels of MIC-1/GDF15 (pg/ml) (Mean ± SD) 1248.48 ± 603.04 1257.62 ± 657.43
Levels of CRP (mg/L) (Mean ± SD) 2.90 ± 5.28 2.96 ± 4.69
Levels of IL-6 (pg/ml) (Mean ± SD) 6.45 ± 9.58 7.34 ± 15.83
Apolipoprotein allele ε4 22.7% (n = 496) b 24.8% (n = 324)
Cardiovascular disease risk score c (Mean ± SD) 17.24 ± 3.58 (n = 501) 17.07 ± 3.63 (n = 322)
Stroke 2.4% (n = 500) 3.1% (n = 322)
Acute myocardial infarction 7.4% (n = 503) 6.2% (n = 324)
Angina 10.0% (n = 501) 12.5% (n = 319)
History of transient ischemic attack d 6.3% (n = 495) 7.0% (n = 313)
History of cancer 39.9% (n = 504) 42.7% (n = 323)
MIC-1/GDF15 = Macrophage Inhibitory Cytokine—1 / Growth Differentiation Factor 15
CRP = C-Reactive Protein
IL-6 = Interleukin-6
SD = standard deviation
a 247 participants received both MRI scans and blood tests at both Waves.
b The number of subjects varied among different measures due to missing data
c Cardiovascular disease (CVD) risk scores were calculated based on Framingham Heart Disease Risk Score, which was a percentage illustrating the
summary of cardiovascular risks of age, sex, systolic blood pressure, use of antihypertensive treatment, cigarette smoking, diabetes mellitus, total
cholesterol, high-density lipoprotein (HDL) cholesterol, and body mass index (BMI). The score ranged from 7 to 28 at wave 1, and 7 to 26 at wave 2.
d The data came from self-report
doi:10.1371/journal.pone.0123399.t001
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The study was approved by the Human Research Ethics Committees of the University of
New South Wales and the South Eastern Sydney and Illawarra Area Health Service. All our
participants gave written informed consent. This has been approved by the Institutional Re-
view Board (IRB).
MIC-1/GDF15 serum levels measurement
The MIC-1/GDF15 serum levels concentration for both Wave 1 and Wave 2 was determined
using an enzyme-linked immunosorbent assay (ELISA) as previously described [40]. Briefly,
the MIC-1/GDF15 sandwich ELISA was established using the mouse MAb 13C4H3 for antigen
capture; and the sheep PAb 233B3-P for detection. Maxisorp 96-well ELISA plates (Nalge
Nunc International, Roskilde, Denmark) were coated with MAb 13C4H3 supernatant diluted
1:5 (final Ig concentration was approximately 20 ng/mL) in coating buffer at 4C for 24 h.
ELISA plates were then washed three times with 300 μL/well of wash buffer. Nonspecific bind-
ing was blocked with 250 μL/well of 1% (wt/vol) BSA in PBS for 2 h at 37 C. rhMIC-1 standard
or serum in Ab dil were then added to the plates (100 μL/well) and incubated for 1 h at 37 C.
The plates were washed three times, followed by the addition of 100 μL/well of the sheep PAb
233B3-P diluted 1:5000 in Ab dil and incubated for 1 h at 37 C. ELISA plates were then washed
three times, and 100 μL/well of biotinylated donkey antisheep IgG diluted to 1:5000 in Ab dil
was added and incubated for 1 h at 37 C. The plates were then developed, as for the direct
ELISA. The concentration of hMIC-1 in the samples was determined by comparison with the
rhMIC-1 standard curve. The standard curve was constructed using standard curve-fitting
software supplied with the microplate reader (Pasteur Diagnostics). The level of rhMIC-1 in
the standard curve was determined on the basis of a comparison of this standard to a master
standard of highly purified recombinant MIC-1. The master standard protein concentration
was determined by an average of eight estimations of total amino acid composition. All samples
were assayed in triplicate on at least two occasions. Results are presented as the mean ± SD.
The CV for all readings was less than 10%.
Magnetic resonance imaging
276 out of the 506 Wave 1 participants were scanned on a Philips 3T Intera Quasar scanner
(Philips Medical Systems, Best, the Netherlands), whereas the remaining 230 Wave 1 and all
Wave 2 participants received MRI scans from a Philips 3T Achieva Quasar Dual scanner. Of
the 247 participants who received both MRI scans and blood tests at both Wave 1 and 2, 133
individuals were scanned by the first scanner at Wave 1 and then by the second scanner at
Wave 2 (i.e. the scans of these people were acquired by the two different scanners at the two
time points), whereas the scans of the rest 112 individuals were from the same scanner at both
Wave 1 and 2. The two scanners were set to the same parameters for T1-weighted MRI acquisi-
tions: TR = 6.39 ms, TE = 2.9 ms, flip angle = 8°, matrix size = 256 × 256, FOV = 256 × 256 ×
190, and slice thickness = 1 mm with no gap in between, yielding 1 × 1 × 1 mm3
isotropic voxels.
Since the participants were recruited randomly, little systematic sampling bias was likely to
be induced by the change of scanners. At Wave 1, participants underwent scans at the two dif-
ferent scanners did not differ in sex (chi-square value = 0.491, p = 0.483), years of education
(p = 0.210), age (p = 0.150), or MIC-1/GDF15 serum levels (p = 0.766). After adjusting age, sex
and years of education, we did not observe any GM volume (p = 0.896), white matter (WM)
volume (p = 0.892) or total intracranial volume (ICV) (p = 0.451) difference between the par-
ticipants scanned on the two scanners. To test if scanner type was a moderator of the relation-
ships being investigated, we included into the model the addition of an interaction term
MIC-1/GDF15 and Gray Matter Volumes
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consisting of the product of scanner type (coded as a dummy variable) and the independent
variable (IV) under investigation (i.e. MIC-1/GDF15 serum levels at Wave 1 or the change in
MIC-1/GDF15 serum levels over two years). All p-values for the interaction term were greater
than 0.074 and partial R-squares less than 1.26% of the explained variance. We should also
point out that, in the regression models for any of these analyses, scanner type, or interaction
terms involving this variable, were not confounded with any of the variables (variance inflation
factor (VIF) values no greater than 1.649). Therefore, the change of scanners did not affect our
results. To adjust for any possible bias introduced by scanners, we coded the two scanners with
one dummy variable, i.e. 1 for the scans acquired on the first scanner, and 2 for those from the
second scanner. Therefore, 276 out of the 506 participants at Wave 1 were assigned with “1”,
and the rest 230 individuals were marked as “2”. This dummy variable was used as a control
variable in all analyses that used data from the two scanners (i.e. Wave 1 cross-sectional analy-
ses and all longitudinal analyses).
Image processing
Freesurfer v5.1.0 (http://surfer.nmr.mgh.harvard.edu/, [41]) was used for extracting global,
total cortical, and lobar volumes. Briefly, the cortical model was set up by using intensity nor-
malization, correction and surface deformation. After applying a series of deformable proce-
dures, cortical thickness was then calculated as the closest distance from the gray/white
boundary to the gray/CSF boundary at each vertex on the tessellated surface. Cortical volume
is calculated as multiplying cortical thickness by cortical surface area.
Subcortical structures were processed by FMRIB Software Library (FSL) v5.0.1 [42]. FSL
was used instead of FreeSurfer for subcortical volumes because of a more robust hippocampal
segmentation in our preliminary analyses; volumes of 92 manually traced bilateral hippocampi
showed stronger correlations with FSL-segmented (r = 0.67 to 0.71) compared to FreeSurfer-
segmented (r = 0.51 to 0.52) hippocampal volumes. The correlation coefficient between FSL
generated and manually traced hippocampal volume was similar to a previous study of 20 par-
ticipants in their mid-30s (r = 0.66, [43]). Another advantage for using FSL was its tools con-
ducting vertex-wise surface analyses on subcortical structures, which was used in the
current study.
Specifically, non-brain tissue was removed by first registering a standard space brain tem-
plate to the individual brain image, and then running an automated skull stripping procedure
based on the SPM5 skull-cleanup tool [44] to obtain the brain. FMRIB’s Integrated Registration
and Segmentation Tool (FIRST v4.1) [45], was then applied to generate 15 subcortical struc-
tures (7 on each hemisphere and brainstem). The FIRST algorithm modeled each participant's
subcortical structure as a surface mesh, using a Bayesian model incorporating a training set of
all images. The boundary of the structure was determined by a correction procedure, using a
Gaussian mixture-model and Markov Random field (for more details, refer to [45]). To reduce
the number of comparisons, the volume of structures on the left and right hemisphere
were combined.
Quality control
The quality of FSL outcomes was controlled by applying ENIGMA protocols (http://enigma.
ini.usc.edu/protocols/imaging-protocols/). Briefly, skull stripping was conducted before run-
ning FIRST to ensure the registration accuracy. After running FIRST, registration was checked
for accuracy; an outline of the templates was projected onto the slices extracted from each of
the coronal, sagittal and axial planes of each linearly transformed scan. We confirmed that the
size and orientation of the individual brain corresponded with the template, and the lobes were
MIC-1/GDF15 and Gray Matter Volumes
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correctly located. For each brain, the volume of each subcortical structure was then extracted.
Segmentations with the volume exceeding mean±1.96SD were then checked for whether the la-
bels accurately cover the full subcortical structures using the FSLVIEW toolbox. FreeSurfer re-
sults were also visually checked for segmentation and registration accuracy using TKMEDIT
toolbox. Scans were excluded if they failed visual quality control. The number of excluded
scans for each structure is shown in S1 Table (in S1_Tables.docx).
Global cognition scores (GCSs)
In MAS, we recruited six cognition domains to evaluate the participants’ neuropsychological
performances: 1) processing speed was assessed by the Wechsler Adult Intelligence Scale-III
Digit Symbol-Coding [46] and Trail Making Test part A (TMT A) [47]; 2)memory was evalu-
ated by Logical Memory Story A (delayed recall) [48], Rey Auditory Verbal Learning Test
(RAVLT) [47], and Benton Visual Retention Test recognition (BVRT) [49]; 3) verbal memory
used the same measures in the memory domain except for BVRT; 4) language was tested by
Boston Naming Test (30 items) [50] and Semantic Fluency Test (animals) [47]; 5) visuo-spatial
ability was from Block Design frim the Wechsler Adult Intelligence Scale—Revised [51]; 6) ex-
ecutive function was evaluated by Controlled Oral Word Association Test (FAS) and Trail
Making Test part B (TMT B) [47].
Raw scores were standardized (i.e. converted to Z-scores), based on the means and SDs of a
normal cognition reference group derived from the cohort. Domain scores were calculated by
averaging the Z-scores of the component tests. GCSs were obtained by averaging domain Z-
scores.
Statistical analyses
In order to examine the associations between MIC-1/GDF15 serum levels and brain structures
on a vertex basis, we carried out shape analyses on both cortical and subcortical structures
using toolboxes from FreeSurfer and FSL.
Subcortical surface analyses were performed by using the vertex analysis function provided
by FMRIB’s Integrated Registration Segmentation Toolkit (FIRST). Briefly, after segmenting
the subcortical structures, the deformable surfaces of deep GM structures were used to auto-
matically parameterize the volumetric labels in terms of meshes. The normalized intensities
along the surface of meshes were sampled and modeled. The shape and appearance model was
based on multivariate Gaussian assumptions. Shape was then expressed as a mean with modes
of variation (principal components). The results were considered to be statistically significant
at areas with p< 0.05, after correcting for multiple comparisons using false discovery rate
(FDR) correction.
We conducted cortical shape analysis using QDEC tool box provided by FreeSurfer (www.
surfer.nmr.mgh.harvard.edu), in which general linear models were applied on a vertex basis.
The results were projected onto the template, which were then corrected for multiple compari-
sons using FDR at a level of 0.05.
The region of interest (ROI) analyses were performed using SPSS v21.0.0 (IBM Corp. Re-
leased 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp). The
distribution of MIC-1/GDF15 serum levels and GM volumes were examined for normality.
Outliers were removed by applying a cut-off of ±3 standard deviations (SDs), i.e. any value ex-
ceeded ±3SD was considered as an outlier, and therefore excluded.
To assess the cross-sectional relationships at each Wave between MIC-1/GDF15 serum lev-
els and brain GM volumes, two sets of multiple linear regression models were fitted. The first
model adjusted for age, sex, years of education, ICV, as well as scanner type when Wave 1
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volumetric measures were used (model 1). The second model included additional control vari-
ables selected from a set of potential confounding variables. The possible confounders include
history of cerebrovascular accident (CVA), transient ischemic attack (TIA), acute myocardial
infarction (AMI), angina, cancer, APOE4 genotype, race, cardiovascular disease (CVD) risk
scores, C-reactive protein (CRP) plasma levels, and interleukin (IL)– 6 serum levels. The selec-
tion of these additional control variables was done using the stepwise procedure for model re-
duction, with the p values for variable entry and removal being set at 0.05 and 0.10,
respectively. Such regression analyses were also performed to examine the extent to which
MIC-1/GDF15 serum levels at Wave 1 predicted changes in GM volumes fromWave 1 to
Wave 2, as well as whether Wave 1 GM volumes predicted changes in MIC-1/GDF15 serum
levels over two years, and a further set of analyses were carried out to investigate the relation-
ships between changes in MIC-1/GDF15 serum levels fromWave 1 to Wave 2 with the corre-
sponding changes in GM volumes across the two Waves. Using the same covariates and
settings, a regression analysis was also carried out to investigate whether the association be-
tween changes in MIC-1/GDF15 and in GM volumes depends on the initial levels of MIC-1/
GDF15, that is whether Wave 1 MIC-1/GDF15 is a moderator of this relationship. This was
done by including in the model MIC-1 baseline levels as well as the interaction product term
between these levels and the change in MIC-1 levels.
The associations between MIC-1/GDF15 serum levels and GCSs were also examined in two
models. In the first model, we controlled for demographic factors, including age, sex and years
of education. The second model further included other possible confounders, including history
of CVA, TIA, AMI, angina, cancer, CVD risk scores, CRP plasma levels and IL-6 serum levels.
The second model used stepwise procedure for model reduction. The possible mediation effects
of the GM ROIs on the relationships of MIC-1/GDF15 serum levels with GCSs were investigat-
ed using Sobel tests.
The analyses were corrected using FDR at a level of 0.05. Possible non-linear effects were ex-
amined by the inclusion of an additional MIC-1/GDF15 serum levels-squared term in the re-
gression models. For these analyses, the MIC-1/GDF15 serum levels were centered, to avoid
multicollinearity between itself and its squared value.
Results
Demographic characteristics
Table 1 presents the demographic characteristics and medical conditions of the study partici-
pants. While all participants at Wave 1 were non-demented, 10 were diagnosed with dementia
at Wave 2. MIC-1/GDF15 serum levels at Wave 1 and Wave 2 were significantly correlated
(n = 315, r = 0.812, p< 0.001), indicating a good test-retest reliability.
The associations between MIC-1/GDF15 serum levels and brain GM
volumes—cross-sectional analyses
Table 2 summarizes the associations between MIC-1/GDF15 serum levels and brain GM vol-
umes at both Wave 1 and 2. In general, MIC-1/GDF15 serum levels showed negative relation-
ships with brain GM volumes. The effects were more consistent and significant for Wave 1
data compared to Wave 2. The difference in the strength of the results could be due in part to
non-random attrition. Logistic regression analysis showed a statistically significant prediction
by MIC-1 levels at Wave 1 of who dropped out of the study by Wave 2 (p = 0.025). Since the
MIC-1/GDF15 serum levels at the two waves are highly correlated (r = 0.812, p< 0.001), this
would tend to remove from the Wave 2 sample individuals who would otherwise have
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relatively higher concentrations of MIC-1/GDF15 and so reduce the correlations with brain
GM volumes at Wave 2. However, despite being statistically significant, the strength of this pre-
diction was small (odds ratio = 1.177, Z-scores of Wave 1 MIC-1/GDF1 levels were used to
avoid the influence of the unit of measurement of Wave 1 MIC-1/GDF15). So whether this
could contribute to explaining the difference between the two waves in the strength of associa-
tions is not clear.
At Wave 1, after FDR correction, all tested ROIs except caudate, putamen and amygdala
showed statistically significant inverse relationships with MIC-1/GDF15 serum levels. Cortical
voxel-based analyses supported this by showing, after FDR correction, significant inverse rela-
tionships of MIC-1/GDF15 serum levels with the following regions: transverse temporal and
superior parietal, as well as some parts of precentral, insula, pars trangularis and pars orbitalis
regions on the right hemisphere (Fig 1). After FDR correction, subcortical vertex-based shape
analyses also showed a similar pattern as ROI analyses; MIC-1/GDF15 serum levels negatively
correlated with most of the left pallidum and bilateral thalami surfaces (Fig 2). At Wave 2,
MIC-1/GDF15 serum levels were significantly inversely associated with total subcortical and
insula GM volumes, but the results did not survive FDR correction. The negative associations
between MIC-1/GDF15 and whole brain, temporal, hippocampus, thalamus, and accumbens
GM volumes, also showed trends towards statistical significance. The cortical and subcortical
voxel-wise analyses did not reach statistical significance at any region at Wave 2 after FDR
Table 2. Regression analyses for the relationships of MIC-1/GDF15 level with brain GM volume at both wave 1 and 2.
Wave 1 Wave 2
Model 1 Model 2 Model 1 Model 2
β p β p β p β p
Whole brain GM -.135 .000* -.132 .000* -.077 .052 -.075 .056
Cortices Total cortical GM -.115 .001* -.112 .001* -.060 .131 -.049 .217
Frontal -.096 .007* -.093 .008* -.034 .453 -.022 .628
Parietal -.116 .001* -.113 .001* -.066 .120 -.054 .207
Temporal -.134 .000* -.131 .000* -.077 .078 -.077 .078
Occipital -.090 .034* -.087 .038* -.018 .716 -.018 .716
Insula -.064 .031* -.064 .031* -.101 .009 -.091 .018
Subcortical structures Total subcortical GM -.120 .003* -.117 .004* -.103 .047 -.099 .050
Hippocampus -.127 .008* -.127 .008* -.111 .062 -.111 .062
Thalamus -.180 .000* -.177 .000* -.114 .054 -.110 .057
Caudate -.023 .604 -.023 .604 .003 .961 .003 .961
Putamen -.042 .364 -.040 .380 -.022 .722 -.022 .722
Pallidum -.140 .007* -.152 .003* -.054 .409 -.041 .507
Amygdala -.051 .323 -.048 .353 -.077 .233 -.077 .233
Accumbens -.209 .000* -.209 .000* -.111 .075 -.106 .081
Brainstem -.124 .002* -.124 .002* -.074 .155 -.062 .225
* statistically signiﬁcant after corrected for multiple comparisons using False Discovery Rate (FDR) at level of 0.05
Model 1: adjusting for age, sex, years of education, scanner (for wave 1 analyses), and intracranial volume (ICV)
Model 2: adjusting for confounders after model reduction using stepwise procedure. The full initial confounder list includes history of cerebrovascular
accident (CVA), transient ischemic attack (TIA), acute myocardial infarction (AMI), angina, cancer, APOE4 genotype, race, cardiovascular (CVD) risk
scores, C-reactive protein (CRP) level, and interleukin (IL)– 6 level.
doi:10.1371/journal.pone.0123399.t002
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correction. None of the ROIs showed a non-linear relationship with MIC-1/GDF15 serum lev-
els at either Wave 1 or Wave 2.
The associations between MIC-1/GDF15 serum levels and brain GM
volumes—longitudinal analyses
Using data fromWave 1 and Wave 2, we first investigated whether MIC-1/GDF15 serum levels
at Wave 1 could predict the GM changes over two years (Table 3). Generally, there was a weak
non-significant trend that a higher MIC-1/GDF15 serum level at Wave 1 was associated with
less cortical and subcortical GM atrophy over two years. The only association reached statisti-
cal significance was between Wave 1 MIC-1/GDF15 serum levels and changes in insula vol-
umes; individuals with higher initial MIC-1/GDF15 tended to have greater insula atrophy in
the following two years. To further examine if higher initial MIC-1/GDF15 serum levels have
protective effects on GM, we categorized both GM volumes (divided by ICV) and MIC-1/
GDF15 serum levels at Wave 1 into high and low groups, but did not observe significantly less
2-year GM atrophy in the participants with higher MIC-1/GDF15 serum levels and more pre-
served GM volumes at Wave 1, compared to the ones with lower MIC-1/GDF15 serum levels
and smaller GM volumes, after FDR correction.
Since the causality between MIC-1/GDF15 and brain atrophy was uncertain, we also tested
the possibility of Wave 1 GM volumes predicting changes in MIC-1/GDF15 serum levels over
two years (Table 4). The changes in MIC-1/GDF15 serum levels over two years were not signif-
icantly associated with the volumes of any tested GM regions at Wave 1.
The associations of MIC-1/GDF15 serum level changes with GM volume changes are pre-
sented in Table 5 and Fig 3. GM volumetric changes of all tested GM structures, except
Fig 1. Vertex-based analyses of associations betweenMacrophage Inhibitory Cytokine—1 (MIC-1/
GDF15) serum levels and cortical volume at Wave 1. The result was adjusted for age, sex, years of
education, scanner, and intracranial volume (ICV) (Model 1). The results were corrected at a false discovery
rate (FDR) of 0.05 and projected onto a semi-inflated brain. Negative correlations are indicated by cyan and
blue, and positive correlations by red and yellow.
doi:10.1371/journal.pone.0123399.g001
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occipital lobe, insula, caudate, putamen, pallidum, accumbens and brainstem, showed signifi-
cantly (p< 0.05) or marginally (p 0.061) negative relationships with the changes in MIC-1/
GDF15 serum levels. After FDR correction, changes in parietal lobe, total cortical, total subcor-
tical, and whole brain GM volumes still showed significant inverse relationships with changes
in MIC-1/GDF15 serum levels, i.e. an increase in MIC-1/GDF15 serum levels was associated
with a decrease of GM volumes. No statistically significant non-linear effects were observed for
the relationships of changes in MIC-1/GDF15 serum levels with changes in any of the
GM volumes.
To examine if the initial MIC-1/GDF15 serum levels at Wave 1 was a moderator of the
strength of the associations between MIC-1/GDF15 serum levels changes and GM changes
(the model is shown in Fig 4), we carried out further regression analyses with the Wave 1 MIC-
1/GDF15 serum levels and the interaction between MIC-1/GDF15 serum levels at Wave 1 and
changes in MIC-1/GDF15 serum levels over two years, also being included in the model. The
results showed that wave 1 MIC-1/GDF15 serum levels was not a moderator of the associations
of changes in MIC-1/GDF15 serum levels with GM volumetric changes over two years.
We did not control for cognition (e.g. Mild Cognitive Impairment (MCI) and Alzheimer’s
Disease (AD)) in our statistical analyses, because we consider cognition changes as an outcome
rather than a cause of brain volume changes. However, there is a possibility that some bio-
chemical conditions associating with the conversion to AD and MCI has common influences
on both MIC-1/GDF15 serum levels and brain volumes. To test this possibility, we repeated all
analyses in a normal ageing sample (excluding MCI and AD participants from the full sample)
with the same covariates described in Section 2.6. In both cross-sectional and longitudinal
Fig 2. Vertex-wise analyses of the relationships between MIC-1/GDF15 serum levels and subcortical structures at Wave 1. The result was after FDR
correction and adjusted for age, sex, years of education, scanner, and intracranial volume (ICV) (Model 1). Regions showing statistical significance were
negatively correlated with MIC-1/GDF15 serum levels. Left pallidum and bilateral thalami survived FDR correction. After FDR correction, the ranges of
statistical significance (p values) were changed to 0–0.043 for left pallidum, 0–0.038 for left thalamus, and 0–0.039 for right thalamus.
doi:10.1371/journal.pone.0123399.g002
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analyses, the majority of statistically significant associations reported for the full sample were
repeated in the analyses of normal ageing participants (S2 Table in S2_Table.docx, S3 Table in
S3_Table.docx, and S4 Table in S4_Table.docx). The results removed the possibility that our
findings could be accounted for by those converting to MCI/AD.
The associations between MIC-1/GDF15 serum levels and GCSs
Using the cognition data, we first tested the relationships between MIC-1/GDF15 serum levels
and the GCSs. Cross-sectionally, MIC-1/GDF15 serum levels were negatively associated with
the GCS at both Waves (at Wave 1, Model 1: β = -.096, p = 0.038, Model 2: β = -0.101,
p = 0.029; at Wave 2, Model 1:β = -0.152, p = 0.011, Model 2: β = -0.134, p = 0.023). Prospec-
tively, the relationship between Wave 1 MIC-1/GDF15 and Wave 2 GCS (controlling for Wave
1 GCS in addition to other control variables) was not statistically significant (Model 1: β =
-0.049, p = 0.194; Model 2: β = -0.045, p = 0.226). Moreover, changes in MIC-1/GDF15 serum
levels over two years was not significantly associated with Wave 2 GCS, after controlling for
Wave 1 GCS (Model 1: β = 0.000, p = 0.991; Model 2: β = -0.003, p = 0.922). The results were
in line with our previous study [16]. Some slight differences in the strength of associations
were possibly due to the significantly smaller sample size in the current study because of ex-
cluding the participants who did not have MRI scans.
The mediation effects of GM volumes on the associations between MIC-
1/GDF15 serum levels and GCSs
Using the Sobel tests, we then tested the possible mediation effects of GM volumes on the sta-
tistically significant relationships between MIC-1/GDF15 and GCSs. Since the mediation
Table 3. Regression analyses for the relationships of MIC-1/GDF15 at wave 1 with the changes in brain GM volume over two years.
Model 1 Model 2
β p β p
Whole brain GM .110 .117 .114 .102
Cortices Total cortical GM .106 .122 .110 .102
Frontal .079 .251 .082 .230
Temporal .061 .400 .064 .375
Parietal .109 .117 .113 .097
Occipital .043 .551 .043 .551
Insula -.161 .028 -.156 .031
Subcortical structures Total subcortical GM .061 .482 .073 .389
Hippocampus .036 .635 .042 .573
Thalamus .046 .539 .046 .539
Caudate .079 .276 .079 .276
Putamen -.013 .867 -.013 .867
Pallidum .057 .456 .057 .456
Amygdala -.015 .852 -.015 .852
Accumbens -.063 .403 -.063 .403
Brainstem .058 .439 .063 .392
Model 1: adjusting for age, sex, years of education, scanner, and ICV
Model 2: adjusting for confounders after model reduction using stepwise procedure. The full confounder list includes history of CVA, TIA, AMI, angina,
cancer, APOE4 genotype, race, CVD risk scores, CRP level, and IL-6 level.
doi:10.1371/journal.pone.0123399.t003
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effects would not exist if the relationships between the independent variable (MIC-1/GDF15
serum levels in our case) and the possible mediator (GM volumes) did not reach statistical sig-
nificance, we only tested the potential mediation effects for the GM regions with statistically
significant associations with MIC-1/GDF15 (Table 6). GM volumes of the whole brain, cortex,
temporal lobe, thalamus and accumbens showed significant mediating effects on the associa-
tions between MIC-1/GDF15 serum levels and GCSs at Wave 1. At Wave 2, insula and total
subcortical GM volumes showed significant relationships with MIC-1/GDF15, but were not
mediators for the associations between MIC-1/GDF15 and GCS.
Discussion
To the best of our knowledge, this is the first study to investigate the relationship between the
MIC-1/GDF15 serum levels and human brain GM volumes, using both cross-sectional and
longitudinal data. After correction for multiple comparisons, GM volumes of most subcortical
and cortical regions examined, with the exception of caudate, putamen and amygdala, were
negatively correlated with MIC-1/GDF15 serum levels at the initiation of the study period
(Wave 1). Over the course of the ensuing two years, after FDR correction, the changes in parie-
tal lobe, total cortical, total subcortical, and whole brain GM volumes were significantly nega-
tively correlated with MIC-1/GDF15 serum level changes. Individuals with higher Wave 1
MIC-1/GDF15 serum levels tend to have less GM volume shrinkage over two years. However,
none of the associations between Wave 1 MIC-1/GDF15 serum levels and GM volumetric
changes over two years reached statistical significance. The negative relationship of MIC-1/
GDF15 serum levels with brain GM volume is consistent with our previous study
Table 4. Regression analyses for the associations betweenWave 1 GM volumes and changes in MIC-
1/GDF15 serum levels.
Model 1 Model 2
Beta P Beta P
Whole brain .005 .946 .001 .989
Total cortical .034 .616 .030 .649
Frontal .016 .797 .009 .890
Parietal .026 .688 .029 .654
Temporal .023 .722 .025 .699
Occipital .055 .404 .048 .461
Insula -.022 .715 -.016 .792
Total subcortical .028 .688 .028 .688
Hippocampus .015 .825 .014 .840
Thalamus .105 .117 .088 .189
Caudate .004 .951 .004 .951
Putamen .015 .816 .015 .816
Pallidum .085 .174 .061 .330
Amygdala .033 .581 .009 .876
Accumbens .116 .075 .116 .075
Brainstem .066 .274 .065 .283
Model 1: adjusting for age, sex, years of education, scanner, and ICV
Model 2: adjusting for confounders after model reduction using stepwise procedure. The full confounder list
includes history of CVA, TIA, AMI, angina, cancer, APOE4 genotype, race, CVD risk scores, CRP level,
and IL-6 level.
doi:10.1371/journal.pone.0123399.t004
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demonstrating a negative relationship between cognition and MIC-1/GDF15 serum levels [16],
and those of other groups investigating the associations of MIC-1/GDF15 with all-cause mor-
tality [52, 53]. We also revealed that GM loss was one of the mechanisms for the linkage be-
tween elevated MIC-1/GDF15 serum levels and cognitive degeneration [16].
In our previous longitudinal study [34], we examined 2-year atrophy of cortical and subcor-
tical structures in the same cohort as the current study, though there were some small varia-
tions on the exact number of scans in each wave due to the availability of particular parameters
and measures. The results showed significant and widespread brain atrophy in two years. The
atrophy pattern is similar to previous benchmark longitudinal studies [35–38]. Therefore, the
current study investigated the contribution of MIC-1/GDF15 to brain volumes based on a sam-
ple with valid brain atrophy patterns.
MIC-1/GDF15 is widely distributed within the CNS and is present in the cerebrospinal fluid
(CSF). Its mRNA and protein have been detected in a variety of brain regions, including cortex,
hippocampus, striatum, pons, and medulla oblongata [20], making it plausible that it has an in-
fluence on brain structures. In adult rats, the protective effects of MIC-1/GDF15 on 6-hydroxy-
dopamine (6-OHDA) lesioned nigrostriatal dopaminergic neurons lasted for at least one
month [20], which indicates that its effects on the brain may be relatively long lasting.
MIC-1/GDF15 has antithetical properties which fuel the debate whether it is beneficial or
harmful [54]. It inhibits the hypokalemia-induced neuron apoptosis [55], but promotes apo-
ptosis of cancer cells [56]. It stimulates vessel development in the context of melanomas [57],
but suppressed angiogenesis in the Matrigel plug assay in vivo [58]. Our finding may indicate
that the effects of MIC-1/GDF15 are complex. Higher serum levels of MIC-1/GDF15 appear to
be associated with some protection against declining GM volume in the future. This finding
Table 5. Regression analyses for the relationships of MIC-1/GDF15 changes with brain GM volume changes over two years.
Model 1 Model 2
Beta p Beta p
Whole brain GM -.235 .000* -.226 .000*
Cortices Total cortical GM -.173 .007* -.165 .008*
Frontal -.130 .042 -.124 .051
Temporal -.146 .031 -.136 .042
Parietal -.171 .008* -.161 .011*
Occipital -.084 .216 -.084 .216
Insula -.088 .198 -.099 .140
Subcortical structures Total subcortical GM -.261 .001* -.234 .002*
Hippocampus -.138 .048 -.130 .061
Thalamus -.149 .031 -.149 .031
Caudate -.074 .271 -.074 .271
Putamen -.099 .159 -.099 .159
Pallidum -.047 .515 -.047 .515
Amygdala -.140 .052 -.140 .052
Accumbens -.106 .129 -.106 .129
Brainstem -.057 .413 -.049 .478
* statistically signiﬁcant after corrected for multiple comparisons using FDR at level of 0.05
Model 1: adjusting for age, sex, years of education, scanner, and ICV
Model 2: adjusting for confounders after model reduction using stepwise procedure. The full confounder list includes history of CVA, TIA, AMI, angina,
cancer, APOE4 genotype, race, CVD risk scores, CRP level change, and IL-6 level change.
doi:10.1371/journal.pone.0123399.t005
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suggests that MIC-1/GDF15 acts as a protective factor. However, higher serum MIC-1/GDF15
levels at Wave 1 were clearly associated with reduced GM volumes. An alternative explanation
is that similar to IL-6, MIC-1/GDF15 might have both pro- and anti-inflammatory properties
in the CNS. Previous studies have found that IL-6, which has both pro- and anti-inflammatory
properties [59, 60], was negatively correlated with brain volumetric measures [10]. Our finding
that the neurotrophic effects of MIC-1/GDF15 might not be able to compensate for CNS injury
may be due to the trophic effects of MIC-1/GDF15 acting on existing neurons rather than pro-
moting their numeric expansion [20].
The observed effect of MIC-1/GDF15 on the CNS could also be due to its impact on the ce-
rebrovascular system. MIC-1/GDF15 has been associated with cardiovascular events [31], in
which atherosclerosis is the most common underlying pathological mechanism. De Jager et al.
[61] reported that removing the gene for MIC-1/GDF15 leads to an increase in atherosclerotic
Fig 3. Associations of MIC-1/GDF15 level changes and cortical volume changes over two years. The
result was adjusted for age, sex, years of education, scanner, and ICV (Model 1). Negative correlations are
indicated by cyan and blue, and positive correlations by red and yellow. The results were after correction for
multiple comparisons using FDR. Volume changes of parts of superior temporal, middle temporal and
superior frontal regions negatively correlated with MIC-1/GDF15 level change over two years.
doi:10.1371/journal.pone.0123399.g003
Fig 4. Themoderation analysis model. A graphical illustration of the moderation analysis of whether the
initial MIC-1/GDF15 serum levels at Wave 1 moderated the strength of the associations between changes in
MIC-1/GDF15 serum levels and GM volumes.
doi:10.1371/journal.pone.0123399.g004
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plaque stability, suggesting that the presence of MIC-1/GDF15 may promote plaque rupture
and consequent thromboembolic or occlusive events that directly impact the CNS. A previous
study had associated atherosclerosis with brain GM atrophy [14], thereby supporting this
mechanism of action.
Previous studies showed that MIC-1/GDF15 may serve to inhibit the late phase of macro-
phage activation [17, 19]. In addition, Johnen et. al. found that MIC-1/GDF15 was likely to be
Table 6. Sobel tests for the mediation effects of the GMmeasures on the statistically significant relationships betweenMIC-1/GDF15 and GCS at
Wave 1 and 2.
Coeff1 SE1 Coeff2 SE2 Sobel SE3 p
Whole brain GM (Wave 1) Model 1 -14.631 3.468 3.957E-6 1E-6 -2.886 2.006E-5 .004
Model 2 -14.348 3.438 3.957E-6 1E-6 -2.871 1.977E-5 .004
Total cortical GM (Wave 1) Model 1 -9.712 2.800 5.097E-6 2E-6 -2.054 2.410E-5 .040
Model 2 -9.450 2.768 5.097E-6 2E-6 -2.042 2.359E-5 .041
Frontal GM (Wave 1) Model 1 -3.132 1.153 1.059E-5 5E-6 -1.670 1.986E-5 .095
Model 2 -3.044 1.148 1.059E-5 5E-6 -1.655 1.948E-5 .098
Parietal GM (Wave 1) Model 1 -2.962 .906 9.330E-6 6E-6 -1.404 1.968E-5 .160
Model 2 -2.889 .899 9.330E-6 6E-6 -1.400 1.926E-5 .162
Temporal GM (Wave 1) Model 1 -2.838 .765 1.725E-5 7E-6 -2.053 2.385E-5 .040
Model 2 -2.760 .754 1.725E-5 7E-6 -2.044 2.329E-5 .041
Occipital GM (Wave 1) Model 1 -.930 .436 1.930E-5 1.2E-5 -1.284 1.398E-5 .199
Model 2 -.903 .434 1.930E-5 1.2E-5 -1.272 1.370E-5 .203
Insula GM (Wave 1) Model 1 -.226 .105 2.933E-5 4.8E-5 -.588 1.128E-5 .557
Model 2 -.226 .105 3.033E-5 4.8E-5 -.606 1.131E-5 .544
Total subcortical GM (Wave 1) Model 1 -1.497 .501 2.209E-5 1.1E-5 -1.667 1.984E-5 .096
Model 2 -1.454 .499 2.209E-5 1.1E-5 -1.654 1.942E-5 .098
Hippocampus GM (Wave 1) Model 1 -.228 .085 1.17E-4 6E-5 -1.577 1.691E-5 .115
Model 2 -.228 .085 1.17E-4 6E-5 -1.577 1.691E-5 .115
Thalamus GM (Wave 1) Model 1 -.517 .123 1.91E-4 4E-5 -3.155 3.130E-5 .002
Model 2 -.508 .122 1.90E-4 4E-5 -3.131 3.083E-5 .002
Pallidum GM (Wave 1) Model 1 -.172 .063 9.283E-5 8.1E-5 -1.057 1.511E-5 .291
Model 2 -.187 .063 9.283E-5 8.1E-5 -1.069 1.624E-5 .285
Accumbens GM (Wave 1) Model 1 -.081 .019 .001 2.66E-4 -2.820 2.873E-5 .005
Model 2 -.081 .019 .001 2.65E-4 -2.826 2.867E-5 .005
Brainstem GM (Wave 1) Model 1 -.724 .229 1.838E-5 2.2E-5 -.808 1.647E-5 .419
Model 2 -.724 .229 1.831E-5 2.2E-5 -.805 1.647E-5 .421
Insula GM (Wave 2) Model 1 -.320 .121 3.075E-5 6.1E-5 -.495 1.987E-5 .620
Model 2 -.288 .121 2.847E-5 6.0E-5 -.465 1.762E-5 .642
Total subcortical GM (Wave 2) Model 1 -1.010 .507 4.253E-5 1.4E-5 -1.666 2.579E-5 .096
Model 2 -.974 .496 3.514E-5 1.5E-5 -1.505 2.274E-5 .132
Coeff1: raw (unstandardized) regression coefﬁcient for the association between MIC-1/GDF15 and GM volumes
SE1: standard error of Coeff1
Coeff2: raw (unstandardized) coefﬁcient for the association between GM volumes and GCSs (the MIC-1/GDF15 serum level is also included in the model
as an independent variable)
SE2: standard error of Coeff2
Sobel: Sobel test statistic
SE3: standard error of the Sobel test statistic
p: p-value for the Sobel test
doi:10.1371/journal.pone.0123399.t006
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produced by atherosclerostic lesions in an attempt to limit or repair the lesions [32]. This may
shed light on the finding that although observing clearly negative associations between MIC-1/
GDF15 serum levels and GM volume at Wave 1 and longitudinally, we found a trend that a
higher MIC-1/GDF15 serum level at Wave 1 was associated with less cortical and subcortical
shrinkage in the ensuing two years.
Although statistically significant negative associations were observed between MIC-1/
GDF15 serum levels and brain GM volumes in the current study, we were unable to conclude
whether MIC-1/GDF15 has direct effects on brain. MIC-1/GDF15 may be a marker of brain
damage due to other reasons, perhaps as a homeostatic response of the body and brain to such
damage which in itself is not involved in pathogeneses, or not sufficient to contain or amelio-
rate the damage. Like other members from TGF-β superfamily, MIC-1/GDF15 is understood
to be up-regulated in the lesion process. In a study of adult rat brains, Schober et al. [21] re-
ported detectable MIC-1/GDF15 mRNA six hours after cryogenic lesion of the cortex, however
no data is available for humans. The negative correlation between MIC-1/GDF15 serum levels
and GM volume in the current report may provide a clue to an analogous result as in animal
models. As a result, the inverse relationship may be due to the fact that GM shrinkage induced
by ageing or neurodegenerative process [34] is perhaps the cause of the elevation of MIC-1/
GDF15 serum levels. This was supported by our finding that MIC-1/GDF15 serum level is a
marker but not predictor of cortical change over two years.
Future longitudinal studies with multiple time points are needed to examine the presence or
absence of a causal relationship between MIC-1/GDF15 serum level change and brain volumet-
ric change in humans. Since the shape analysis showed a relatively widespread association of
bilateral thalami with MIC-1/GDF15 serum levels, which was also supported by our ROI analy-
ses, further investigations on white matter (WM) fibers, especially on thalamo-cortico-thalam-
ic circuits, is worthy of further examination.
Since the number of participants was lower at Wave 2, the statistical power was limited for
the analyses using Wave 2 data. Despite the lack of statistical significance, all Wave 2 results
were consistently in the same direction as the corresponding Wave 1 findings. The follow-up
of the participants in the present study was only for two years, and it is possible that a longer
follow-up is necessary to examine the predictive ability of MIC-1/GDF15 serum levels as has
been seen in other studies [62]. It is also possible that there is a real but small relationship be-
tween initial MIC-1/GDF15 serum levels and changes in brain GM volumes, but that these
were not shown to be statistically significant due to a lack of power. A power analysis shows
that our sample size would be adequate to reliably detect relatively small effects sizes of beta
greater than about 0.18, with power of 0.8 and alpha rate of 0.05. Larger samples would be re-
quired, to reliably detect real effect sizes smaller than this value. Including CSF levels of MIC-
1/GDF15 in the analyses would be helpful. There were too few dementia patients in our sample
to determine what the serum or CSF levels of MIC-1/GDF15 are once dementia develops.
Although we found statistically significant associations between MIC-1/GDF15 serum levels
and GM volumes, a relatively small portion (no more than 5.2%) of GM volumes and their
changes over time can be explained by MIC-1/GDF15 serum levels and their changes in our
sample (S5 Table in S5 Table.docx, S6 Table in S6 Table.docx, and S7 Table in S7 Table.docx).
Therefore, the clinical utility of this cytokine as a marker of age-related brain decline needs
further investigations.
In conclusion, the present study found an inverse relationship between MIC-1/GDF15
serum levels and brain GM volumes both cross-sectionally and longitudinally. The GM decline
was one of the reasons for the negative associations between MIC-1/GDF15 serum levels
and cognition.
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